VBLT - VBL Therapeutics gets safety committee nod to proceed with phase 3 ovarian cancer trial

VBL Therapeutics (NASDAQ:VBLT) said an independent data safety monitoring committee recommended to continue a phase 3 trial of its drug Ofra-vec to treat platinum-resistant ovarian cancer, following a review of data from 370 patients. The company noted that enrollment in the phase 3 trial, dubbed OVAL, was completed with 409 patients enrolled at centers in the U.S., Europe, Israel and Japan. The trial is evaluating a combination of ofra-vec (ofranergene obadevovec or VB-111) and paclitaxel agianst placebo plus paclitaxel. The study has two main goals — progression free survival (PFS) and overall survival. The company expects to report top-line data related to PFS part in H2 this year, which is expected to support a regulatory approval application to the FDA.

For further details see:

VBL Therapeutics gets safety committee nod to proceed with phase 3 ovarian cancer trial